SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation

Cell Reports

Volumn 4, Issue 2, 2013, Pages 362-375

  O'Rourke, Jacqueline Gire ^a,b   Gareau, Jaclyn R ^c   Ochaba, Joseph ^a,b   Song, Wan ^b   Raskó, Tamás ^d   Reverter, David ^c   Lee, John ^e   Monteys, Alex Mas ^e   Pallos, Judit ^b   Mee, Lisa ^a   Vashishtha, Malini ^a,b   Apostol, Barbara L ^a   Nicholson, Thomas Peter ^f,j   Illes, Katalin ^a   Zhu, Ya Zhen ^a   Dasso, Mary ^g   Bates, Gillian P ^h   Difiglia, Marian ⁱ   Davidson, Beverly ^e   Wanker, Erich E ^d   Marsh, J Lawrence ^b   Lima, Christopher D ^c   Steffan, Joan S ^a,b   Thompson, Leslie M ^a,b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK STRUCTURAL BIOLOGY CENTER   (United States)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY OF IOWA   (United States)

^f Enzo Life Sciences (UK) Ltd   (United Kingdom)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j VIVA Bioscience Ltd   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; PROTEASOME; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 1; SUMO 1 PROTEIN; SUMO 2 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DROSOPHILA; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; STRESS;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; DROSOPHILA; FEMALE; HELA CELLS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; MUTATION; NERVE TISSUE PROTEINS; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84880769535     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.06.034     Document Type: Article

References (69)

1. Atwal R.S., Truant R. A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy. Autophagy 2008, 4:91-93.
2. Bernier-Villamor V., Sampson D.A., Matunis M.J., Lima C.D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002, 108:345-356.
3. Björkqvist M., Wild E.J., Tabrizi S.J. Harnessing immune alterations in neurodegenerative diseases. Neuron 2009, 64:21-24.
4. Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A., Eriksson J.E., Sistonen L. Invivo identification of sumoylation sites by a signature tag and cysteine-targeted affinity purification. J.Biol. Chem. 2010, 285:19324-19329.
5. Bohren K.M., Nadkarni V., Song J.H., Gabbay K.H., Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J.Biol. Chem. 2004, 279:27233-27238.
6. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
7. Bruderer R., Tatham M.H., Plechanovova A., Matic I., Garg A.K., Hay R.T. Purification and identification of endogenous polySUMO conjugates. EMBO Rep. 2011, 12:142-148.
8. Cubeñas-Potts C., Matunis M.J. SUMO: a multifaceted modifier of chromatin structure and function. Dev. Cell 2013, 24:1-12.
9. Datwyler A.L., Lättig-Tünnemann G., Yang W., Paschen W., Lee S.L., Dirnagl U., Endres M., Harms C. SUMO2/3 conjugation is an endogenous neuroprotective mechanism. J.Cereb. Blood Flow Metab. 2011, 31:2152-2159.
10. Ehrnhoefer D.E., Sutton L., Hayden M.R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 2011, 17:475-492.
11. Gareau J.R., Lima C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 2010, 11:861-871.
12. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
13. Geoffroy M.C., Hay R.T. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat. Rev. Mol. Cell Biol. 2009, 10:564-568.
14. Gidalevitz T., Ben-Zvi A., Ho K.H., Brignull H.R., Morimoto R.I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311:1471-1474.
15. Goehler H., Lalowski M., Stelzl U., Waelter S., Stroedicke M., Worm U., Droege A., Lindenberg K.S., Knoblich M., Haenig C., et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 2004, 15:853-865.
16. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
17. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J.Neurosci. 2008, 28:6182-6195.
18. Gu X., Greiner E.R., Mishra R., Kodali R., Osmand A., Finkbeiner S., Steffan J.S., Thompson L.M., Wetzel R., Yang X.W. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
19. Hari K.L., Cook K.R., Karpen G.H. The Drosophila Su(var)2-10 locus regulates chromosome structure and function and encodes a member of the PIAS protein family. Genes Dev. 2001, 15:1334-1348.
20. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 2012, 21:5280-5293.
21. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 2004, 73:355-382.
22. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J.Neurosci. 2004, 24:7999-8008.
23. Kim Y.M., Jang W.H., Quezado M.M., Oh Y., Chung K.C., Junn E., Mouradian M.M. Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J.Neurol. Sci. 2011, 307:157-161.
24. Krumova P., Weishaupt J.H. Sumoylation in neurodegenerative diseases. Cell. Mol. Life Sci. 2013, 70:2123-2138.
25. Labbadia J., Cunliffe H., Weiss A., Katsyuba E., Sathasivam K., Seredenina T., Woodman B., Moussaoui S., Frentzel S., Luthi-Carter R., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J.Clin. Invest. 2011, 121:3306-3319.
26. Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., Sun B., Gafni J., Ellerby L.M., Trottier Y., et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J.Biol. Chem. 2010, 285:8808-8823.
27. La Spada A.R., Taylor J.P. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 2010, 11:247-258.
28. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998, 8:397-403.
29. Lee Y.J., Johnson K.R., Hallenbeck J.M. Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia. PLoS One 2012, 7:e47787.
30. Liu B., Shuai K. Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol. Sci. 2008, 29:505-509.
31. Lois L.M., Lima C.D. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 2005, 24:439-451.
32. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lakshmi Srinidhi C.L., Barnes G., Taylor S.A., James M., Groot N., MacFarlane H., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
33. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
34. Marsh J.L., Thompson L.M. Drosophila in the study of neurodegenerative disease. Neuron 2006, 52:169-178.
35. McMillan L.E., Brown J.T., Henley J.M., Cimarosti H. Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model. Neurosci. Lett. 2011, 502:201-208.
36. Oh Y., Kim Y.M., Mouradian M.M., Chung K.C. Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation. Brain Res. 2011, 1381:78-89.
37. Olsen S.K., Capili A.D., Lu X., Tan D.S., Lima C.D. Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 2010, 463:906-912.
38. Pennuto M., Palazzolo I., Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum. Mol. Genet. 2009, 18(R1):R40-R47.
39. Reverter D., Lima C.D. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 2005, 435:687-692.
40. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., Thompson L.M. Thefirst 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 2007, 16:61-77.
41. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
42. Rytinki M.M., Kaikkonen S., Pehkonen P., Jääskeläinen T., Palvimo J.J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 2009, 66:3029-3041.
43. Saitoh H., Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J.Biol. Chem. 2000, 275:6252-6258.
44. Schipper-Krom S., Juenemann K., Reits E.A. The ubiquitin-proteasome system in huntington's disease: are proteasomes impaired, initiators of disease, or coming to the rescue?. Biochem. Res. Int. 2012, 2012:837015.
45. Schmidt D., Müller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. USA 2002, 99:2872-2877.
46. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 2005, 5:593-605.
47. Sivanandam V.N., Jayaraman M., Hoop C.L., Kodali R., Wetzel R., van der Wel P.C. The aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils. J.Am. Chem. Soc. 2011, 133:4558-4566.
48. Sontag E.M., Lotz G.P., Agrawal N., Tran A., Aron R., Yang G., Necula M., Lau A., Finkbeiner S., Glabe C., et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J.Neurosci. 2012, 32:11109-11119.
49. Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G., Guérardel C., Dejean A., Leprince D. An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol. Cell. Biol. 2007, 27:2661-2675.
50. Steffan J.S. Does Huntingtin play a role in selective macroautophagy?. Cell Cycle 2010, 9:3401-3413.
51. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 2000, 97:6763-6768.
52. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
53. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
54. Stelzl U., Worm U., Lalowski M., Haenig C., Brembeck F.H., Goehler H., Stroedicke M., Zenkner M., Schoenherr A., Koeppen S., et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005, 122:957-968.
55. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
56. Sun H., Hunter T. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search. J.Biol. Chem. 2012, 287:42071-42083.
57. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
58. Tatham M.H., Matic I., Mann M., Hay R.T. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci. Signal. 2011, 4:rs4.
59. Thompson L.M., Aiken C.T., Kaltenbach L.S., Agrawal N., Illes K., Khoshnan A., Martinez-Vincente M., Arrasate M., O'Rourke J.G., Khashwji H., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 2009, 187:1083-1099.
60. Turner C., Schapira A.H. Mitochondrial matters of the brain: the role in Huntington's disease. J.Bioenerg. Biomembr. 2010, 42:193-198.
61. Ulrich H.D. SUMO Protocols. Preface. Methods Mol. Biol. 2009, 497:v-vi.
62. Waldron-Roby E., Ratovitski T., Wang X., Jiang M., Watkin E., Arbez N., Graham R.K., Hayden M.R., Hou Z., Mori S., et al. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J.Neurosci. 2012, 32:183-193.
63. Wanker E.E., Scherzinger E., Heiser V., Sittler A., Eickhoff H., Lehrach H. Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol. 1999, 309:375-386.
64. Warby S.C., Doty C.N., Graham R.K., Carroll J.B., Yang Y.Z., Singaraja R.R., Overall C.M., Hayden M.R. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum. Mol. Genet. 2008, 17:2390-2404.
65. Warby S.C., Doty C.N., Graham R.K., Shively J., Singaraja R.R., Hayden M.R. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell. Neurosci. 2009, 40:121-127.
66. Wilkinson K.A., Nakamura Y., Henley J.M. Targets and consequences of protein SUMOylation in neurons. Brain Res. Brain Res. Rev. 2010, 64:195-212.
67. Yang W., Thompson J.W., Wang Z., Wang L., Sheng H., Foster M.W., Moseley M.A., Paschen W. Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics. J. Proteome Res. 2012, 11:1108-1117.
68. Zheng Z., Diamond M.I. Huntington disease and the huntingtin protein. Prog. Mol. Biol. Transl. Sci. 2012, 107:189-214.
69. Zheng Z., Li A., Holmes B.B., Marasa J.C., Diamond M.I. An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J.Biol. Chem. 2013, 288:6063-6071.